Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)

Generalized Anxiety Disorder Clinical Trial

— fMRI  

Official title:

Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01607710
• Other study ID #: DIEF003523.2
• Status: Completed
• Phase: N/A
• First received: May 25, 2012
• Last updated: September 4, 2014
• Start date: July 2012
• Est. completion date: June 2014

Study information

• Verified date: March 2013
• Source: Hartford Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The investigators are seeking to locate the brain regions of interest in generalized anxiety disorder (GAD) using both structural (sMRI) and functional magnetic resonance imaging (fMRI). The MRI will be used to measure changes in blood flow in the brain while at rest and while completing tasks designed to elicit symptoms of anxiety. Results from a nonclinical control group and a GAD group will be compared to determine whether they exhibit different areas of brain activity during the tasks.

Description:

20 healthy controls and 20 participants with GAD will be recruited. Each participant will undergo an MRI session that will last approximately 2 hours. The structural MRI will be used when the participant is at rest. During the functional MRI (fMRI), a computer screen inside the scanner will display four tasks the participant must complete: (1)Gambling Task, (2)Risk & Ambiguity Task, (3)Reading Emotion from the Eyes (REE) Task, and (4)Emotional Counting Task.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: June 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Generalized Anxiety Disorder(GAD)Group:

Inclusion Criteria:

• Clinical diagnosis of Generalized Anxiety Disorder

• Hamilton Anxiety Rating Scale score of 18 or higher

• Hamilton Rating Scale for Depression score of 17 or less

• Fluency in English

• Capacity to understand the nature of the study and willingness to sign informed consent for

Exclusion Criteria:

• History of epilepsy or head trauma (Loss of consciousness>5 minutes) with the past 6 months

• Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis or brain surgery

• A review of patient medications by the study physician indicates an increased risk of seizure

• An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency

• Substance use disorder or posttraumatic stress disorder (PTSD) within the past 6 months

• Lifetime bipolar disorder, obsessive-compulsive disorder (OCD), psychotic disorder, mental retardation, or pervasive development disorder

• Any psychotic features, including dementia or delirium

• Medication change within past 3 months

• Current serious suicidal or homicidal ideation, and/or serious suicidal attempt within past 6 months

• Serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study

• Any contraindication for participation in MRI scan

Nonclinical Control Group:

Inclusion Criteria:

• Absence of any psychiatric diagnosis

Exclusion Criteria:

• History of epilepsy or head trauma (Loss of Consciousness>5 minutes) with the past 6 months

• Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis or brain surgery

• A review of patient medications by the study physician indicates an increased risk of seizure

• An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency

• Substance use disorder or PTSD within the past 6 months

• Lifetime bipolar disorder, OCD, psychotic disorder, mental retardation, or pervasive development disorder

• Any psychotic features, including dementia or delirium

• Medication change within past 3 months

• Current serious suicidal or homicidal ideation, and/or serious suicidal attempt within past 6 months

• Serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study

• Any contraindication for participation in MRI scan

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Anxiety Disorders
• Generalized Anxiety Disorder

Locations

Country	Name	City	State
United States	Hartford Hospital	Hartford	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Hartford Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brain activation while undergoing the fMRI	Main effects for each condition will be calculated to elucidate brain activations relevant to the tasks. Random effect 2 sample t-tests will assess group differences (i.e., GAD patients vs. healthy controls) to identify regions that demonstrate hyperactivation in patients.	Throughout the fMRI	No